Seunghyun Cheon

Dr. Seunghyun Cheon

orcid

Research Focus & Metrics

Representative Publications

View All Publications
29 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
SCSeunghyun Cheon
Seunghyun Cheon
SOSang-Hyeon Oh
Sang-Hyeon Oh
JKJung-Tae Kim
Jung-Tae Kim
HCHan-Gon Choi
Han-Gon Choi
HPHyo Jung Park
Hyo Jung Park
JCJee Eun Chung
Jee Eun Chung
This study aimed to investigate the activity of a nutrition support team (NST) and the trends of multi-chamber bag (MCB) and customized parenteral nutrition (PN) with NST consultations in South Korea. Data were obtained from the National Inpatient Sample Cohort between 2015 and 2020. Three datasets were constructed for NST consultation, MCB-PN product prescriptions, and aseptic preparation of total PN. The intersections of the NST consultation and each PN dataset were compiled into MCB-PN with NST or customized PN with a NST sub-dataset, respectively. Using personal identifiers, the patients’ characteristics were evaluated in the NST cohort. A total of 91,384 reimbursements and 70,665 patients were included. The NST activity had increased by more than 50% over 6 years. Approximately 70% and 11%, respectively, of the NST cohort were classified into two subgroups: MCB-PN with NST (M-NST) and customized PN with NST (C-NST). M-NST had many elderly patients with cancer and showed a higher in-hospital mortality than C-NST (12.6% vs. 9.5%). C-NST included a larger number of patients under the age of 5 years, and the hospitalization period was more extended than M-NST (26.2 vs. 21.2 days). The present study showed that NST activities and the proportion of PN with NST consultation are gradually increasing in South Korea.

1 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SCSeunghyun Cheon
Seunghyun Cheon
JPJiyeon Park
Jiyeon Park
DODosol Oh
Dosol Oh
YKYoung Seo Kim
Young Seo Kim
JCJee Eun Chung
Jee Eun Chung
Background: This study aimed to evaluate the risk of upper gastrointestinal (UGI) adverse events (AEs) associated with oral anticoagulants (OACs) and identify potential interactions with cardiovascular (CV) drugs. Methods: Individual case safety reports (ICSRs) from the FDA Adverse Event Reporting System from July 2014 to December 2023 were analyzed. Dataset I was constructed to assess the associations between OACs and UGI AEs using disproportionality analysis. Dataset Ⅱ included OAC-related ICSRs to explore potential interactions with CV drugs through logistic regression. Positive signals were defined as potential associations identified by disproportionality analysis metrics, such as reporting odds ratios (RORs) or adjusted RORs (aRORs) accounting for confounders. Results: Dataset I included 12,905,290 ICSRs, and a positive signal for dabigatran was detected with an ROR of 1.19 (95% CI, 1.13–1.25). A total of 364,044 OAC-related ICSRs were included in dataset II. At the pharmacologic drug class level, several positive signals were identified, represented as aRORs with 95% CIs: for warfarin, amiodarone analogs (1.22; 1.04–1.43); for apixaban, angiotensin-converting enzyme inhibitors (1.34; 1.24–1.45), angiotensin receptor blockers (1.23; 1.14–1.33), dihydropyridine calcium channel blockers (1.30; 1.21–1.41), and digitalis glycosides (1.72; 1.49–2.00); and for edoxaban, angiotensin receptor blockers (1.88; 1.48–2.37), amiodarone analogs (1.73; 1.06–2.85), and anti-platelets (1.56; 1.20–2.03). No signals were observed for rivaroxaban or dabigatran. At the individual drug level, 62 OAC-CV pairs were identified as having potential interactions. Conclusions: Drug-specific interaction profiles should be considered to ensure safe and personalized use of OACs in clinical practice.

28 May 2025 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
SCSeunghyun Cheon
Seunghyun Cheon
SCSeo-Yong Choi
Seo-Yong Choi
KKKyu Ri Kim
Kyu Ri Kim
HCHan-Gon Choi
Han-Gon Choi
JCJee Eun Chung
Jee Eun Chung
Background: As a potent opioid analgesic, fentanyl transdermal patches (FTDs) have been widely used in patients with moderate to severe pain. However, increasing concerns about the opioid epidemic have made it important to strengthen the rational use and management of FTDs. Objective: Our objective was to investigate the trends in the use of FTD and to evaluate potentially inappropriate FTD use in patients with noncancer pain, based on established evaluation criteria, referring various recommendations and guidelines. Methods: A nationwide cross-sectional study was conducted using a national insurance claims database from 2014 to 2020. The study included patients who were prescribed FTDs at least once a year in an outpatient setting, while excluding cancer or pediatric patients. To identify potentially inappropriate use, we developed evaluation criteria based on the established recommendations for the safe use of prescription opioids in patients with noncancer pain and assessed each patient’s compliance. The working-age and older adult groups were compared to evaluate the differences in FTD use, and modified Lorenz curves and Gini coefficients were used to assess the equality of FTD use. Results: A total of 5386 patients and their 19,800 reimbursements were included in the study. The number of patients with FTDs decreased from 58.6 to 53.7 per 100,000 registrants between 2014 and 2020. Meanwhile, the number of reimbursements increased by 7.4%, from 203.2 to 218.1 per 100,000 registrants during the same period. The working-age patients had an average of 3.9 reimbursements per year, with an average morphine milligram equivalent per day (MME/day) of 64.4 for each reimbursement. The older adult patients had an average of 3.5 reimbursements per year, and their average MME/day was 47.9. As a result of applying the evaluation criteria, 567 (24.5%) working-age patients and 531 (17.3%) older adult patients were identified as potentially inappropriate FTD users. Among patients with multiple FTD prescriptions, the working-age group with potentially inappropriate FTD use had significantly higher estimated MME/day than the older adult group (P<.001). The modified Lorenz curve showed that more than 70% of the total FTDs used in the working-age group were consumed by those with potentially inappropriate FTD use, while older adult group with potentially inappropriate FTD use accounted for less than 50% of the total older adult patients. The working-age patients also had a higher Gini coefficient than the older adult group, indicating unequal use of FTDs (0.461 vs 0.406). Conclusions: Although the number of patients receiving FTD prescriptions has decreased during the study period, the total amount of FTDs consumed increased, suggesting that caution is warranted. This study also highlights the potential for inappropriate FTD use in working-age patients. Further research is needed to quantify and qualify the risk factors in patients with potentially inappropriate use, given the clinical rationale associated with prescribing FTDs.